Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC)
- PDF / 1,551,300 Bytes
- 15 Pages / 610 x 792 pts Page_size
- 33 Downloads / 136 Views
BioMed Central
Open Access
Research
Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment Milton W Taylor*1, Takuma Tsukahara1, Jeanette N McClintick2, Howard J Edenberg2 and Paul Kwo3 Address: 1Department of Biology, Indiana University, Bloomington, IN. 47401, USA, 2Department of Biochemistry and Molecular Biology and Center for Medical Genomics, Indiana University School of Medicine, Indianapolis, IN 46202, USA and 3Department of Medicine, Hepatology Unit, Indiana University School of Medicine, Indianapolis, IN 46202, USA Email: Milton W Taylor* - [email protected]; Takuma Tsukahara - [email protected]; Jeanette N McClintick - [email protected]; Howard J Edenberg - [email protected]; Paul Kwo - [email protected] * Corresponding author
Published: 5 November 2008 Journal of Translational Medicine 2008, 6:66
doi:10.1186/1479-5876-6-66
Received: 16 September 2008 Accepted: 5 November 2008
This article is available from: http://www.translational-medicine.com/content/6/1/66 © 2008 Taylor et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract Background and Aims: This study determined the kinetics of gene expression during the first 10 weeks of therapy with Pegylated-interferon-alfa2b (PegIntron™) and ribavirin (administered by weight) in HCV patients and compared it with the recently completed Virahep C study [1,2] in which Peginterferon-alfa2a (Pegasys™) and ribavirin were administered. Methods: RNA was isolated from peripheral blood monocytes (PBMC) from twenty treatment-naïve patients just before treatment (day 1) and at days 3, 6, 10, 13, 27, 42 and 70 days after treatment. Gene expression at each time was measured using Affymetrix microarrays and compared to that of day 1. Results: The expression of many genes differed significantly (p ≤ 0.001 and changed at least 1.5-fold) at days 3 (290 probes) and 10 (255 probes), but the number dropped at days 6 (165) and 13 (142). Most genes continued to be up regulated throughout the trial period. A second group of genes, including CXCL10, CMKLR1 (chemokine receptor 1), TRAIL, IL1Rα and genes associated with complement and lipid metabolism, was transiently induced early in treatment. CDKN1C (cyclin kinase inhibitor 1) was induced early but repressed at later times. Genes induced at later times were mostly related to blood chemistry and oxygen transport. By week 10, 11 of the patients demonstrated a positive response to therapy, and the final sustained viral response (SVR) was 35%. The levels of gene induction or decrease was very similar to that previously reported with Pegasys/ribavirin treatment. Conclusion: The response to Pegintron/ribavirin was similar to that reported for
Data Loading...
